TAK:NYSE, Takeda Pharmaceutical Company Limited
TAK stock overview
Takeda Pharmaceutical Company Limited (TAK:NYSE) closed at $20.24 on October 23, 2026,
down 0.59% on the day.
The stock trades 0.7% below its 52-week high of $20.39
and 55.8% above its 52-week low of $12.99.
Over the past year, it gained 44.5%.
Takeda Pharmaceutical Company Limited is part of the Health Care sector (Major Pharmaceuticals).
Key figures
- Price
- $20.24
- Day change
- -0.59%
- Volume
- 2,099,176
- Average volume
- 2,839,335
- Market cap
- 64B+
- 52-week range
- $12.99 – $20.39
- 50-day average
- $18.54
- 200-day average
- $17.43
Price action over the past year
In 252 trading sessions since October 23, 2025, TAK closed higher on 128 days (51%).
Its best day was July 2, 2026 (+5.14%) and its worst was June 1, 2026 (-4.82%).
It never moved 10% or more in a single session.
Recent signals
TAK news
-
Oct 23, 2026:
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study
-
Oct 22, 2026:
Keros Therapeutics Eyes 2027 DMD Data as Rinvatercept Takes Center Stage
-
Oct 22, 2026:
Asian Equities Traded in the US as American Depositary Receipts Fall Sharply in Thursday Trading
-
Oct 20, 2026:
Stephen K. Brannan, MD, and John D. Young Appointed to Slate Medicines Board of Directors
-
Oct 20, 2026:
Disease Clearance Data Might Change The Case For Investing In Takeda (TSE:4502)
-
Oct 20, 2026:
Asian Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
-
Oct 19, 2026:
Merck KGaA bets on RNAi with $1.3B Silence buyout
-
Oct 19, 2026:
First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO (vedolizumab) Prolongs Time to First Disease-Related Complication
About Takeda Pharmaceutical Company Limited
Takeda is Japan's largest pharmaceutical company, with annual revenue around $16 billion and a focus on four therapeutic areas: oncology, gastroenterology, vaccines, and neurology. Roughly 40% of its revenue comes from Japan. The Millennium acquisition (2008) brought rights to Velcade, Ninlaro, and Entyvio. The Nycomed acquisition (2011) expanded Takeda's exposure to Europe and emerging markets. Other notable products include Azilva (blood pressure), leuprorelin (prostate cancer), and Trintellix (depression).
Similar stocks
Find more stocks like TAK with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.